Lenvatinib
- Generic Name
- Lenvatinib
- Brand Names
- Lenvima 10, Kisplyx, Lenvima
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O4
- CAS Number
- 417716-92-8
- Unique Ingredient Identifier
- EE083865G2
- Background
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...
- Indication
Lenvatinib is indicated for the treatment of the following cancerous conditions:
Differentiated Thyroid Cancer (DTC)
Renal Cell Carcinoma (RCC)
Hepatocellular Carcinoma (HCC)
Endometrial Carcinoma
- Associated Conditions
- Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
- Associated Therapies
- -
TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 336
- Registration Number
- NCT03905967
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
- Conditions
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Humanity & Health Medical Group Limited
- Target Recruit Count
- 30
- Registration Number
- NCT03899428
- Locations
- 🇭🇰
Humanity & Health Research Centre, Hong Kong, Hong Kong SAR, Hong Kong
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
- Conditions
- Interventions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 487
- Registration Number
- NCT03898180
- Locations
- 🇺🇸
Seattle Cancer Care Alliance ( Site 0003), Seattle, Washington, United States
🇺🇸Northwest Georgia Oncology Centers PC ( Site 0707), Marietta, Georgia, United States
🇺🇸Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0002), New York, New York, United States
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
- Conditions
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 842
- Registration Number
- NCT03884101
- Locations
- 🇺🇸
UCLA Hematology and Oncology Clinic (Westwood) ( Site 0233), Los Angeles, California, United States
🇺🇸University of Rochester ( Site 0238), Rochester, New York, United States
🇧🇷Faculdade de Medicina da Universidade Federal de Minas Gerais ( Site 2708), Belo Horizonte, Minas Gerais, Brazil
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-05-12
- Target Recruit Count
- 50
- Registration Number
- NCT03841201
- Locations
- 🇩🇪
Hannover Medical School, Hannover, Germany
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 297
- Registration Number
- NCT03838796
- Locations
- 🇨🇳
Huashan hospital, Shanghai, China
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 761
- Registration Number
- NCT03829319
- Locations
- 🇺🇸
Thomas Jefferson University Hospital ( Site 0548), Philadelphia, Pennsylvania, United States
🇵🇱Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0603), Warszawa, Mazowieckie, Poland
🇦🇷Sanatorio Parque ( Site 0365), Rosario, Santa Fe, Argentina
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 623
- Registration Number
- NCT03829332
- Locations
- 🇮🇹
Universita Magna Grecia ( Site 0230), Catanzaro, Italy
🇮🇱Bnei Zion Medical Center ( Site 0227), Haifa, Heifa, Israel
🇮🇱Sourasky Medical Center ( Site 0225), Tel Aviv, Israel
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
- Conditions
- Interventions
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 674
- Registration Number
- NCT03820986
- Locations
- 🇦🇺
Princess Alexandra Hospital ( Site 0454), Wooloongabba, Queensland, Australia
🇺🇸University of North Carolina - Cancer Hospital ( Site 0751), Chapel Hill, North Carolina, United States
🇨🇳Yunnan Cancer Hospital ( Site 0604), Kunming, Yunnan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.